Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VentiRx Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

VentiRx Pharmaceuticals Inc. has been working since 2007 to develop TLR8 agonists for allergic rhinitis and cancer, while considering how they might also be used in other indications. The company reported positive data from Phase I clinical trials in both areas within the past year, but has recently decided to move forward in cancer only.

You may also be interested in...

Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer

VentiRx’s immunotherapy approach has created a compound, VTX-2337, offering potential in a variety of cancers and complementary to numerous standard-of-care backbones.

Cyterix Pharmaceuticals Inc.

Cyterix Pharmaceuticals Inc. thinks it has found a way to safely increase the maximum tolerated dose of gemcitabine, a widely used cancer drug. The prodrugs that Cyterix is developing are meant to be activated by specific variants within a huge family of enzymes all classified as cytochrome P450 enzymes.

Tocagen Inc.

Tocagen Inc. is confident that it possesses the proper technology to at last realize some of gene therapy's early promise. Instead of seeking to neuter vectors so they cannot spread, Tocagen deploys a retroviral replicating vector containing genes that let viruses enter and replicate in cancer cells. The retrovirus the company has modified for its purposes was isolated from mice, and no equivalent has been found in humans.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts